…
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -72.92M | -57.98M | -42.82M | -32.18M | -8.93M |
| Net income | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M |
| Selling general administrative | 20.55M | 16.65M | 7.68M | 7.18M | 4.63M |
| Selling and marketing expenses | - | - | 16.29M | 26.07M | 31.09M |
| Gross profit | - | -1.65M | -0.62M | -4.17M | -1.40M |
| Reconciled depreciation | 1.38M | 1.65M | 1.48M | 1.01M | 0.36M |
| Ebit | -72.86M | -57.88M | -42.67M | -32.04M | -8.48M |
| Ebitda | -71.48M | -56.23M | -41.19M | -31.03M | -8.12M |
| Depreciation and amortization | 1.38M | 1.65M | 1.48M | 1.01M | 0.36M |
| Operating income | -84.04M | -58.02M | -44.65M | -32.83M | -15.61M |
| Other operating expenses | 84.04M | 58.02M | 44.65M | 32.83M | 15.61M |
| Interest expense | 0.06M | 0.11M | 0.15M | 0.14M | 0.22M |
| Tax provision | 1.23M | 0.00M | - | - | - |
| Interest income | 11.30M | 4.26M | 0.58M | 0.15M | 0.00M |
| Net interest income | 11.23M | 4.15M | 0.43M | 0.01M | -0.45M |
| Income tax expense | 1.23M | - | 0.38M | - | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 84.04M | 58.02M | 44.65M | 32.83M | 15.61M |
| Cost of revenue | - | 1.65M | 0.62M | 4.17M | 1.40M |
| Total other income expense net | 11.12M | 0.03M | 1.82M | 0.65M | 6.68M |
| Net income from continuing ops | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 261.04M | 152.91M | 39.40M | 47.21M | 32.88M |
| Other current assets | 3.56M | 5.62M | 2.12M | 1.08M | 0.56M |
| Total liab | 9.71M | 12.13M | 124.03M | 92.86M | 47.84M |
| Total stockholder equity | 251.33M | 140.78M | -84.64M | -45.65M | -14.96M |
| Other current liab | 7.34M | 7.85M | 38.66M | 5.81M | 1.95M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -222.74M | -148.59M | -90.60M | -47.78M | -15.60M |
| Other assets | - | - | 69.38M | 0.00M | 0.00M |
| Cash | 253.80M | 141.24M | 28.77M | 35.97M | 28.06M |
| Total current liabilities | 9.67M | 11.61M | 40.89M | 7.84M | 4.12M |
| Current deferred revenue | - | - | -0.88M | - | -0.35M |
| Net debt | -252.52M | -137.94M | -24.43M | -30.17M | -27.01M |
| Short term debt | 1.23M | 2.78M | 1.82M | 1.45M | 0.35M |
| Short long term debt total | 1.28M | 3.30M | 4.34M | 5.79M | 1.05M |
| Other stockholder equity | 474.16M | 289.35M | 5.98M | 2.13M | 0.64M |
| Total current assets | 257.36M | 146.86M | 30.88M | 37.04M | 28.62M |
| Net receivables | - | - | - | 0.27M | 2.70M |
| Accounts payable | 1.09M | 0.98M | 0.41M | 0.57M | 1.81M |
| Accumulated other comprehensive income | -0.10M | 0.01M | -0.01M | 0.00M | -42.61M |
| Non currrent assets other | 1.12M | 0.16M | 1.29M | 0.61M | 0.60M |
| Non current assets total | 3.68M | 6.05M | 8.52M | 10.17M | 4.26M |
| Capital lease obligations | 1.28M | 3.30M | 4.34M | 5.79M | 1.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.16M | -0.28M | -2.09M | -2.12M |
| Total cashflows from investing activities | -0.14M | -0.16M | -0.28M | -0.27M | -2.12M |
| Net borrowings | -0.49M | -0.47M | -0.50M | -0.39M | 3.61M |
| Total cash from financing activities | 173.35M | 171.71M | 33.75M | 0.26M | 41.42M |
| Net income | -74.15M | -57.98M | -42.82M | -0.03M | -8.93M |
| Change in cash | 113.04M | 112.47M | -7.20M | -96.72M | 26.84M |
| Begin period cash flow | 141.83M | 29.36M | 36.55M | 189.57M | 1.81M |
| End period cash flow | 254.87M | 141.83M | 29.36M | 92.85M | 28.65M |
| Total cash from operating activities | -60.08M | -59.08M | -40.68M | -97.21M | -12.45M |
| Issuance of capital stock | 173.10M | 94.60M | 34.12M | 38.02M | 37.81M |
| Depreciation | 1.38M | 1.65M | 1.48M | 0.00M | 0.36M |
| Other cashflows from investing activities | 0.07M | - | - | - | - |
| Other cashflows from financing activities | -0.48M | 77.59M | 0.12M | 0.39M | 37.81M |
| Capital expenditures | 0.21M | 0.16M | 0.28M | 0.27M | 2.12M |
| Change in working capital | -0.07M | -10.28M | -0.58M | -7.40M | 1.92M |
| Stock based compensation | 10.50M | 3.49M | 1.12M | 0.00M | 0.64M |
| Other non cash items | 2.27M | 4.04M | 0.13M | -89.78M | -6.45M |
| Free cash flow | -60.29M | -59.24M | -40.96M | -97.47M | -14.58M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic, Inc. |
0.91 4.51% |
20.98 | - | - | - | 2.60 |
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 |
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Alise S. Reicin M.D., Ph.D. | President, CEO, Secretary & Director | 1961 |
| Mr. Daniel Lochner M.B.A. | Chief Financial Officer | 1982 |
| Dr. Marcella Kuhlman Ruddy M.D., M.S. | Chief Medical Officer | 1963 |
| Mr. Washington Alves M.S. | Senior Vice President of Technical Operations | NA |
| Dr. Peter McNamara Ph.D. | Chief Scientific Officer | 1972 |
| Ms. Geraldine Peters-Wiles | Senior Vice President of Human Resources | NA |
| Mr. Anthony Muslin M.D. | Chief Development Officer | NA |
| Dr. Marc Schwabish Ph.D. | Chief Business Officer | 1980 |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.